Convergent synthesis of a helical, prehairpin HR1 trimer from HIV gp41

Journal of Peptide Science

Volumn 16, Issue 9, 2010, Pages 465-472

  Lu, Rong Jian ^a   Mader, Catherine J ^a   Schneider, Stephen E ^a   Tvermoes, Nicolai ^a   Kang, Myung Choi ^a   Dwyer, John J ^a   Wilson, Karen L ^a   Matthews, Thomas J ^a   Delmedico, Mary K ^a   Bray, Brian ^a  

^a Trimeris Inc   (United States)

Author keywords

Convergent synthesis; Oligomer; Peptides; Prehairpin gp41 HR1 trimer; Protein synthesis

Indexed keywords

BENZENE DERIVATIVE; FLUORIDE; VIRUS GLYCOPROTEIN;

ARTICLE; CIRCULAR DICHROISM; DEPROTECTION REACTION; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; SYNTHESIS; THERMOSTABILITY;

HIV ENVELOPE PROTEIN GP41; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77957298477     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1262     Document Type: Article

References (53)

1. (a) Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor. Science 2001; 291: 884;
2. (b) Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93: 681;
3. (c) D'Souza MP, Cairns JS, Plaeger SF. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA 2000; 284: 215;
4. (d) Hughson FM. Enveloped viruses: a common mode of membrane fusion? Curr. Biol. 1997; 7: R565;
5. (e) Freed EO and Martin MA. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 1995; 270: 23883-23886.
6. Moore JP, Trkola A., Dragic T., Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 1997; 9: 551-562.
7. Zhao XB. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl. Acad. Sci. U.S.A. 2000; 97: 14172.
8. (a) Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 9770-9774;
9. (b) Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 15613-15617;
10. (c) Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS. Inhibiting HIV- 1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999; 99: 103-115.
11. (a) Furuta RA, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 1998; 5: 276-279;
12. (b) Muñoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell. Biol. 1998; 140: 315-323;
13. (c) Koshiba T., Chan DC. The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J. Biol. Chem. 2003; 278: 7573-7579;
14. (d) Eckert DM, Kim PK. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl Acad. Sci. U.S.A. 2001; 98: 11187-11192.
15. (a) Louis JM, Bewley CA, Clore GM. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J. Biol. Chem. 2001; 276: 29485-29489;
16. (b) Louis JM, Nesheiwat I, Chang L, Clore GM, Bewley CA. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 2003; 278: 20278-20285;
17. (c) Dwyer JJ, Wilson KL, Martin K, Seedorff JE, Hasan A, Medinas RJ, Davison DK, Feese MD, Richter HT, Kim H, Matthews TJ, Delmedico MK. Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency. Protein Sci. 2008; 17: 633-643. (Pubitemid 351480857)
18. Kliger Y, Shai Y. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J.Mol. Biol. 2000; 295: 163-168.
19. Ferrer ME, Kapoor TM, Strassmaier TL, Weissenhorn W., Skehel JJ, Oprian DT, Schreiber SL, Wiley DC, Harrison SC. Selection of gp41- mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. 1999; 6: 953-960;
20. (b) Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 1995; 2: 1075-1082.
21. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV gp41. Nature 1997; 387: 426-430. (Pubitemid 27227210)
22. (a) Xu W, Taylor JW. A template-assembled model of the N-peptide helix bundle for HIV-1 gp41 with high affinity for C-peptide. Chem. Biol. Drug Des. 2007; 70: 319-328;
23. (b) Bianchi E, Finotto M, Ingallinella P, Hrin R, Carella AV, Hou XS, Schleif WA, Miller MD, Geleziunas R, Pessi A. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 12903-12908;
24. (c) Lebl M. (ed). 2009; Breaking Away, Proceedings of the 21st American Peptide Symposium. American Chemical Society, 244-245;
25. (d) Nakahara T, Nomura W, Ohba K, Ohya A, Tanaka T, Hashimoto C, Narumi T, Murakami T, Yamamoto N, Tamamura H. Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies. Bioconjug. 2010; 21: 709-714.
26. Grove A, Mutter M, Rivier JE, Montal M. Template-assembled synthetic proteins designed to adopt a globular, four-helix bundle conformation form ionic channels in lipid bilayers. J. Am. Chem. Soc. 1993; 115: 5919-5924.
27. (a) Handel T, DeGrado WF. De novo design of a Zn 2+binding protein. J. Am. Chem. Soc. 1990; 112: 6710-6711;
28. (b) Handel TM, Williams SA, DeGrado WF. Metal ion-dependent modulation of the dynamics of a designed protein. Science 1993; 261: 879-885.
29. (a) Ghadiri MR, Soares C, Choi C. Design of an artificial fourhelix bundle metalloprotein via a novel ruthenium(II)-assisted self-assembly process. J. Am. Chem. Soc. 1992; 114: 4000-4002;
30. (b) Ghadiri RM, Case MA. De novo design of a novel heterodinuclear three-helix bundle metalloprotein. Angew Chem. Int. Ed. Engl. 1993; 32: 1594-1597.
31. (a) Goodman M, Feng Y, Melacini GA, Taulane JP. A template-induced incipient collagen-like triple-helical structure. J. Am.Chem. Soc. 1996; 118:5156-5157;
32. (b) Kwak J, Capua AN, Locardi EE, Goodman M. TREN (tris(2-aminoethyl) amine): an effective scaffold for the assembly of triple helical collagen mimetic structures. J. Am. Chem. Soc. 2002; 124: 14085-14091.
33. Kilway KV, Siegel JS. Control of functional group proximity and directionbyconformationalnetworks: synthesisandstereodynamics of persubstituted arenes. Tetrahedron 2001; 57: 3615-3627.
34. 1H NMR spectroscopy. J. Am. Chem. Soc. 2004; 126: 16456-15465;
35. (b) Cabell LA, Best MD, Lavigne JJ, Schneider SE, Perreault DM, Monahan MK, Anslyn EV. Metal triggered fluorescence sensing of citrate using a synthetic receptor. J. Chem. Soc., Perkin Trans 2 2001; 3: 315-323.
36. (a) Schneider SE, O'Neil SN, Anslyn EV. Coupling rational design with libraries leads to the production of an ATP selective chemosensor. J. Am. Chem. Soc. 2000; 122: 542-543;
37. (b) Schmuck C, Schwegmann M. A molecular flytrap for the selective binding of citrate and other tricarboxylates in water. J. Am. Chem. Soc. 2005; 127: 3373-3379.
38. Szabo T, O'Leary BM, Rebek J, Jr. Self-assembling sieves. Angew Chem. Int. Ed. Engl 1999; 37: 3410-3413.
39. Zhong Z, Anslyn EV. Controlling the oxygenation level of hemoglobin by using a synthetic receptor for 2,3-bisphosphoglycerate. Angew Chem. Int. Ed. Engl 2003; 46: 3005-3008.
40. (a) Dwyer JJ, Hasan A, Wilson KL, White JM, Matthews TJ, Delmedico MK. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 2003; 42: 4945-4953;
41. (b) Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 2004; 54: 333-340;
42. (c) Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 2005; 79: 12447-12454.
43. (a) Debnath AK, Radigan L, Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 1999; 42: 3203-3209;
44. (b) Naicker KP. Synthesis and anti-HIV-1 activity of 4-[4-(4,6- bisphenylamino-triazin-2-ylamino)-5-methoxy- 2-methylphenylazo]-5- hydroxynaphthalene-2,7-disulfonic acid and its derivatives. Bioorg. Med. Chem. 2004; 12: 1215-1220;
45. (c) Mo H, Konstantinidis AK, Stewart KD, Dekhtyar T, Ng T, Swift K, Matayoshi ED, Kati W, Kohlbrenner W, Molla A. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. Virology 2004; 329: 319-327.
46. Wallace KJ, Hanes R, Anslyn E, Morey J, Kilway KV, Siegel J. Preparation of 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene from two versatile 1,3,5-tri(halosubstituted) 2,4,6-triethylbenzenederivatives. Synthesis 2005; 2080-2083.
47. Chan WC, White PD (eds). Fmoc Solid Phase Peptide Synthesis, a Practical Approach. Oxford University Press: Oxford, 2000; 215-228.
48. (a) Bray B. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2003; 2: 587-593;
49. (b) Schneider SE, Bray BL, Mader CJ, Friedrich PE, Anderson MW, Taylor TS, Boshernitzan N, Niemi TE, Fulcher BC, Whight SR, White JM, Greene RJ, Stoltenberg LE, Lichty M. Development of HIV fusion inhibitors. J. Pept. Sci. 2005; 11: 744-753.
50. Chhabra SR, Hothi B, David J, Evans DJ, White PD, Bycroft BW, Chan WC. An appraisal of new variants of Dde amine protecting group for solid phase peptide synthesis. Tetrahedron Lett. 1998; 39: 1603.
51. (a) Carpino LA, Sadat-Aalaee D, Chao HG, DeSelms RH. [(9-Fluorenylmethyl) oxy]carbonyl (FMOC) amino acid fluorides. Convenient new peptide coupling reagents applicable to the FMOC/tert-butyl strategy for solution and solid-phase syntheses. J. Am. Chem. Soc. 1990; 112: 9651-9652;
52. (b) Carpino LA, Beyermann M, Wenschuh H, Bienert M. Peptide synthesis via amino acid halides. Acc. Chem. Res. 1996; 29: 268;
53. (c) Wenschuh H, Beyermann M, Winter R, Bienert M, Ionescu D, Carpino LA. Fmoc amino acid fluorides in peptide synthesis - Extension of themethod to extremely hindered amino acids. Tetrahedron Lett. 1996; 37: 5483-5486. (Pubitemid 26241066)